A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and Rationale
Elisa Andrini(University of Bologna), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino), Fabrizio Artioli(Roche (Switzerland)), Corrado Ficorella(University of L'Aquila), Fausto Barbieri(University of Modena and Reggio Emilia), Francesco Gelsomino(Azienda USL di Bologna), Francesca Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Karim Rihawi(Azienda USL di Bologna), Michele Tognetto(University of Aberdeen), Matteo Brighenti(Azienda Ospedaliero-Universitaria Careggi), Ida Colantonio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Marcello Tiseo(University of Parma), Giuseppe Lamberti(Dana-Farber Cancer Institute), Andrea Bonetti(Italian Oncology Group of Clinical Research), Carlo Genova(Ospedale Policlinico San Martino), Alessandro Follador(Ospedale Santa Maria della Misericordia di Udine), Giulia Pasello(University of Padua), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 7
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931